retatrutide glp-1 gip glucagon triple agonist Cagrilintide vs Compared Today, we shared new data

AOD-9604 Side Effects and Complications Currently, only two studies (METAOD005 and METAOD006) have investigated the long-term safety of AOD-9604

Department of Health and Human Services HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026 (January 2, 2026) www.hhs.gov CompHealth Interstate Medical Licensure Compact States List for 2026 (January 8, 2026) comphealth.com Florida Department of Health Telehealth FAQs: Out-of-State Provider Registration (Current as of 2025) flhealthsource.gov MedicalDirector Co

SURMOUNT-5 trial: 2.6% mean weight loss Glapp users: 3.4% mean weight loss Relative improvement: +30.8% Week 12 Results Semaglutide weight loss comparison at 12 weeks: Glapp users achieved 7.5% vs 5.9% in SURMOUNT-5 trial

When examining a composite cardio outcomes endpoint (death from CV disease, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina), the ELIXA trial suggested that GLP-1s did not increase cardiovascular event risk (hazard ratio of 1.02)